| 1. |
- Almén, Anja, 1964, et al.
(author)
-
OPTIMISATION OF OCCUPATIONAL RADIATION PROTECTION IN IMAGE-GUIDED INTERVENTIONS: EXPLORING VIDEO RECORDINGS AS A TOOL IN THE PROCESS
- 2016
-
In: Radiation protection dosimetry. - : Oxford University Press (OUP). - 1742-3406 .- 0144-8420. ; 169:1-4, s. 425-429
-
Journal article (peer-reviewed)abstract
- The overall purpose of this work was to explore how video recordings can contribute to the process of optimising occupational radiation protection in image-guided interventions. Video-recorded material from two image-guided interventions was produced and used to investigate to what extent it is conceivable to observe and assess dose-affecting actions in video recordings. Using the recorded material, it was to some extent possible to connect the choice of imaging techniques to the medical events during the procedure and, to a less extent, to connect these technical and medical issues to the occupational exposure. It was possible to identify a relationship between occupational exposure level to staff and positioning and use of shielding. However, detailed values of the dose rates were not possible to observe on the recordings, and the change in occupational exposure level from adjustments of exposure settings was not possible to identify. In conclusion, the use of video recordings is a promising tool to identify dose-affecting instances, allowing for a deeper knowledge of the interdependency between the management of the medical procedure, the applied imaging technology and the occupational exposure level. However, for a full information about the dose-affecting actions, the equipment used and the recording settings have to be thoroughly planned.
|
|
| 2. |
- Sandblom, Viktor, 1987, et al.
(author)
-
Gemcitabine potentiates the anti-tumour effect of radiation therapy on medullary thyroid cancer
- 2016
-
In: 4th Swedish Cancer Research Meeting, 7-8 november 2016, Gothenburg, Sweden..
-
Conference paper (other academic/artistic)abstract
- BACKGROUND Most patients diagnosed with medullary thyroid cancer (MTC) present with metastatic disease and the 10-year survival for these patients is only about 40%. Since many MTCs overexpress somatostatin receptors, one option for these patients is systemic treatment with radiolabelled somatostatin analogues (e.g. 177Lu-octreotate). In addition, the nucleoside gemcitabine has shown anti-tumour activity in MTC. The aim of this study was to investigate potential synergistic effects of combining gemcitabine with irradiation for treatment of MTC. MATERIALS & METHODS Nude mice carrying a patient-derived MTC (GOT2) was divided into treatment groups. They received radiation therapy (as external beam radiotherapy (EBRT) or 177Lu-octreotate) and gemcitabine both as single-agent treatment and in combination. The radiation dose and the amount of gemcitabine were kept low to enable detection of any synergistic effects. Tumour volume was followed and compared with that in untreated mice. RESULTS The largest treatment effect was seen for the animals receiving a combination of both EBRT and gemcitabine. Given as single-agent treatment, both EBRT and gemcitabine resulted in a reduction in tumour growth arrest or even a reduction in tumour volume. The animals treated with only 177Lu-octreotate showed similar response as the control group. CONCLUSIONS It is possible that an additive or even synergistic effect on tumour tissue would be achieved when combining gemcitabine with irradiation for treatment of patients with MTC. Further studies should be performed to evaluate the possibility of using 177Lu-octreotate for treatment of MTC, both as single-agent treatment or in combination with gemcitabine.
|
|
| 3. |
|
|
| 4. |
- Sandblom, Viktor, 1987, et al.
(author)
-
Treatment of medullary thyroid cancer using a combination of radiation and gemcitabine
- 2016
-
In: 62nd Annual International Meeting Radiation Research Society 2016. Big Island, Hawaii, USA, October 16-19, 2016.
-
Conference paper (other academic/artistic)abstract
- INTRODUCTION Medullary thyroid cancer (MTC) is a very rare type of cancer and patients often present with metastatic disease at the time of diagnosis. In contrast to other types of thyroid cancers, MTC originates from C-cells and therefore lacks the iodine pump NIS. This means that MTC cannot be treated with radioiodine, which otherwise is a common systemic treatment method for thyroid cancer. Instead, the use of radiolabelled somatostatin analogues (e.g. 177Lu-octreotate) might be an option, since many MTCs overexpress somatostatin receptors. Furthermore, the nucleoside analogue gemcitabine has previously been used to treat MTC. The aim of this study was to investigate potential synergistic effects of combining irradiation with gemcitabine for treatment of MTC. METHODS The patient-derived MTC cell line GOT2 was transplanted to BALB/c nude mice, which received radiation therapy alone, gemcitabine alone or a combination of both. Radiation therapy was given either as external beam radiotherapy or as i.v. injection of 177Lu-octreotate. The tumour volume was followed and compared with that in untreated mice. The radiation dose and the amount gemcitabine were chosen to give low treatment effect as single treatment to enable detection of any additive or synergistic effects. RESULTS Overall, the animals receiving a combination of both external beam radiotherapy and gemcitabine showed the largest reduction in tumour size over time. Both gemcitabine and external beam radiotherapy alone gave a clear detrimental effect on tumour growth compared with the control group, while the animals receiving only 177Lu-octreotate showed similar response as the control group, possibly due to a too low amount of injected activity. CONCLUSION The results indicate that an additive or even synergistic effect can be achieved by combining radiation with gemcitabine for treatment of MTC. Further studies should be made evaluating the full potential of combining gemcitabine with 177Lu-octreotate.
|
|
